PitchSend

Nuvectis Pharma Investor Presentation Deck

Significant Single Agent Activity in Squamous Cell Cancers NXP900 demonstrated robust antitumor activity in xenograft models of squamous cell cancers Average Tumor Volume (mm³) 700 600 500 400 300 200 100 0 Esophageal Cancer Baseline NuvectisPharma, Inc. Vehicle Control NXP900 (40 mg/kg) Day 3 Day 6 Day 8 Day 10 Day 13 Day 15 Day 17 Time Day 20 Day 22 Day 24 Day 27 KYSE70 cells (YES1 gene amplification is a known genetic alteration) Head and Neck Cancer (tongue) Average Tumor Volume (mm³) 700 600 500 400 300 200 100 0 Vehicle Control NXP900 (40 mg/kg) Day 3 Baseline Day 6 Day 8 Day 10 Day 13 Day 15 Day 17 Time Day 20 Day 22 Day 24 Day 27 Cal27 cells (Heterozygous FAT1 copy loss is a known genetic alteration) 18

View entire presentation